COVID-19 and nicotine as a mediator of ACE-2
- PMID: 32350104
- PMCID: PMC7191112
- DOI: 10.1183/13993003.01261-2020
COVID-19 and nicotine as a mediator of ACE-2
Abstract
α7-nAChR may upregulate ACE-2
Conflict of interest statement
Conflict of interest: J.M. Leung has nothing to disclose. Conflict of interest: C.X. Yang has nothing to disclose. Conflict of interest: D.D. Sin reports grants from Merck, personal fees for advisory board work from Sanofi-Aventis and Regeneron, grants and personal fees for lectures from Boehringer Ingelheim and AstraZeneca, personal fees for lectures and advisory board worm from Novartis, outside the submitted work.
Figures
Comment in
-
Could the smoking gun in the fight against COVID-19 be the (rh)ACE-2?Eur Respir J. 2020 Jul 16;56(1):2001560. doi: 10.1183/13993003.01560-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32398309 Free PMC article.
-
Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond.Eur Respir J. 2020 Aug 13;56(2):2001610. doi: 10.1183/13993003.01610-2020. Print 2020 Aug. Eur Respir J. 2020. PMID: 32554535 Free PMC article.
Comment on
-
ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19.Eur Respir J. 2020 May 14;55(5):2000688. doi: 10.1183/13993003.00688-2020. Print 2020 May. Eur Respir J. 2020. PMID: 32269089 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous